Tysabri Progressive Multifocal Leukoencephalopathy Settlement: Statute of Limitations for Tysabri in Ohio

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Exposure Concerns

The legacy of mass production in the pharmaceutical industry has long been intertwined with the dissemination of general health and science information, providing a foundation for public understanding of therapeutic benefits and risks. This heritage established a framework where broad health education preceded detailed scrutiny of specific product outcomes. As manufacturing scales and distribution networks expand, the focus naturally shifts from generalized health promotion to the nuanced realities of long-term exposure. In the context of Tysabri, a biologic therapy developed for chronic conditions, the transition from general health discourse to occupational exposure concern becomes particularly salient. The drug’s association with progressive multifocal leukoencephalopathy (PML) has prompted legal and regulatory attention, especially regarding the statute of limitations for claims in Ohio. This pivot reflects a broader pattern: as mass production enables widespread use, the legacy of general health information must accommodate the specific risks faced by individuals exposed to such therapies over time. The concern now centers on how historical exposure, documented through routine health monitoring, intersects with legal timelines for seeking redress. This shift underscores the need to reconcile the initial promise of therapeutic innovation with the delayed recognition of adverse outcomes, moving from abstract health education to concrete exposure-based liability considerations.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations, including the statute of limitations, is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for PML have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, weighing expected benefit against PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in immunocompromised patients and is caused by the JC virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation may include progressive neurological deficits such as weakness, cognitive changes, visual disturbances, or coordination problems. Diagnosis often involves MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, PML can still occur, and the outcome is often severe disability or death.

Mechanism of PML and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing JC virus reactivation and uncontrolled infection in the brain. This immunosuppressive effect is particularly pronounced in patients with anti-JCV antibodies, as the virus can remain latent and reactivate under reduced immune pressure. The label notes that patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, prior use of immunosuppressants compounds this risk by further compromising immune function. From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central issue. The boxed warning is prominent, and the drug is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether these warnings were sufficiently communicated to individual patients or whether healthcare providers adequately monitored for early signs of PML.

Statute of Limitations for Tysabri Claims in Ohio

For affected patients in Ohio, settlement-related considerations often depend on the timeline between Tysabri exposure and documented harm. PML can develop after varying durations of treatment, from a few months to several years, as noted for herpes infections in the label (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label specifically identifies longer treatment duration, especially beyond two years, as a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In Ohio, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered. For PML, this discovery date may be when symptoms first appeared or when a formal diagnosis was made. Given the progressive nature of PML, early symptoms may be subtle, and the clock may start when a reasonable person would have connected the symptoms to Tysabri use. Patients and their families should consult with legal counsel to determine the applicable deadlines, as failure to file within the statute of limitations can bar recovery.

Settlement Considerations for PML Patients

Settlement considerations for affected patients may include compensation for medical expenses, lost wages, pain and suffering, and long-term care needs. The severity of PML—often leading to death or severe disability—means that damages can be substantial. However, settlements may also depend on factors such as the adequacy of the warning provided to the patient, the presence of risk factors like anti-JCV antibodies, and the duration of Tysabri therapy. The label emphasizes that physicians should consider whether the expected benefit of Tysabri is sufficient to offset the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). If a patient was not adequately informed of this risk or if monitoring was insufficient, this could strengthen a claim. In summary, Tysabri-associated PML is a serious adverse event with well-defined risk factors and a clear mechanistic basis. For Ohio patients, the statute of limitations requires prompt action after diagnosis. Legal and medical evaluation should consider the timeline of exposure, the presence of risk factors, and the adequacy of warnings. The evidence underscores the importance of careful risk-benefit assessment and vigilant monitoring for any neurological changes during Tysabri therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Ohio?

In Ohio, the statute of limitations for personal injury claims, including those related to pharmaceutical products like Tysabri, is generally two years from the date the injury was discovered or should have been discovered. For PML, this discovery date may be when symptoms first appeared or when a formal diagnosis was made. It is crucial to consult with legal counsel to determine the applicable deadlines, as failure to file within the statute of limitations can bar recovery.

What are the primary risk factors for developing PML from Tysabri?

Three primary risk factors for PML have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, weighing expected benefit against PML risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.